Pricing Log in Create free account
Friday 6 November 2026 Export YCBD’s income statement to Excel — free account

cbdMD, Inc.

YCBD Healthcare Drug Manufacturers Specialty & Generic

cbdMD, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $19.2 million, down 1.50% from fiscal 2024.

Revenue
+20.6%
EPS
+47.6%
Free cash flow
+34.8%

Quarter to June 2026, against a year earlier

0.41 0.02 +5.13%
Market cap
$4.4M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
6/9
Altman Z
−21.65
Beneish M
−2.51
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.28
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 — — — — — — — — — — —
Insider Ownership 5.15%

Capital & Financial Ratios $m

Size
Market Cap 4.35
Revenue ttm 20.93
Net income ttm (2.89)
Free cash flow ttm (2.41)
Net debt Q (2.12)
Valuation
P/E 0.00
Forward P/E (1.16) (negative: loss-making)
Price / sales 0.19
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.49
Financial health
Current ratio Q 2.50 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 96.24
Growth
Revenue growth Q +20.55% (above 0%: growing)
Operating income growth Q −24.96% (below 0%: shrinking)
EPS, this year +69.72% (at or above 15%: strong)
EPS, next year A +42.42% (at or above 15%: strong)
Revenue, next year A +14.22% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 0.6×; over the ten years it ranged from 0.0× in 2023 to 163× in 2019.
P/S against its own 10 years 24.06%
10-year low 10-year high
P/B against its own 10 years 18.58%
10-year low 10-year high
EV/Sales against its own 10 years 25.03%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 2 2 2 2
Receivables 1 1 1 2
Inventory 4 2 3 3
Other — — — —
8 6 7 8
2023 2024 2025 Q'26
Payables 2 2 1 1
ST’ Debt — — — —
Other — — — —
5 9 3 3

Compound Annual Growth %

10y 5y 3y
Sales — (14.45%) (18.46%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (38.05%) (38.74%)

EPS $

Dec Mar Jun Sep Year
’26 (0.04) (0.08) (0.11) — —
’25 (1.76) (1.90) (0.21) (0.08) (1.09)
’24 (5.36) (10.80) (1.20) (1.19) (14.32)
’23 (28.83) (13.92) (9.28) (72.48) (106.56)
’22 (126.13) (36.04) (198.20) (90.09) (446.85)
’21 (64.86) (86.49) 7.21 (14.41) (169.37)
’20 162.16 144.14 (64.86) (57.66) 100.90
Fiscal quarters ending in the months shown.

Revenue $m

Dec Mar Jun Sep Year
’26 5 6 6 — —
’25 5 5 5 5 19
’24 5 4 5 5 19
’23 6 6 6 6 24
’22 9 10 9 8 35
’21 12 12 11 10 44
’20 10 9 11 12 42
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Dec Mar Jun Sep Year
’26 (1) (1) 0 — —
’25 0 0 (1) 0 (1)
’24 0 (1) 0 0 0
’23 (2) (2) 0 0 (4)
’22 (5) (5) (2) (2) (15)
’21 (2) (3) (5) (4) (14)
’20 (5) (4) (1) 0 (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Dec Mar Jun Sep Year
’26 (1) (1) 0 — —
’25 0 0 (1) 0 (2)
’24 0 (1) 0 0 (1)
’23 (2) (2) 0 0 (5)
’22 (6) (5) (3) (2) (16)
’21 (2) (3) (5) (4) (14)
’20 (5) (6) (1) 0 (12)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 4 0 24 42 44 35 24 19 19 21 +28.3% 22 29 — +22.1%
Gross margin, % 20.33 69.71 77.35 61.37 62.96 67.41 63.09 62.01 61.57 62.37 57.68 +42.0 pt
EBT (4) (1) (2) (48) 11 (24) (70) (23) (4) (2) (3) (6.9%)
EBT margin, % (191.39) (30.42) (391.44) (202.05) 26.99 (54.61) (197.96) (94.96) (18.99) (10.63) (13.80) +180.8 pt
Net income (4) (1) 0 (51) 13 (23) (70) (23) (4) (2) (3) (6.9%)
Per share, $
Per share, $ Revenue 244.77 355.16 21.35 476.85 341.91 291.68 213.27 95.55 36.14 4.77 1.97 (35.4%)
Earnings (405.45) (138.33) (18.02) (1,016.22) 100.90 (169.37) (446.85) (106.56) (14.32) (1.09) (0.31) (48.2%)
Cash flow (349.07) (184.90) (259.21) (310.03) (87.06) (92.42) (90.16) (17.02) (0.65) (0.36) (0.21) (53.4%)
Capex (15.34) (0.63) (17.84) (25.17) (10.78) (2.24) (4.15) (1.18) (0.54) (0.05) (0.02) (47.6%)
Free cash flow (364.41) (185.54) (277.06) (335.20) (97.83) (94.66) (94.31) (18.19) (1.19) (0.41) (0.23) (53.0%)
Book value (35.27) 408.64 652.06 758.15 646.38 676.34 189.30 35.73 3.64 1.80 0.77 n/m
Shares, m 0 0 0 0 0 0 0 0 1 4 10 +98.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 3.77 0.00 0.00 0.00 0.00 0.00 0.00 0.4
P/S 5.60 5.60 101.00 2.99 2.11 2.57 0.38 0.09 0.19 0.56 0.19 12.1
P/B 4.89 4.89 3.31 1.88 1.11 1.11 0.43 0.23 1.86 1.50 0.49 2.1
EV/Sales 5.60 5.60 88.59 2.81 1.79 1.98 0.19 0.06 0.18 0.57 0.21 10.7
EV/FCF (10.82) (10.82) (6.83) (3.99) (6.22) (6.07) (0.44) (0.29) (5.86) (6.44) (1.74) (5.8)
Cash, $m
Cash, $m Operating cash flow (3) (2) (6) (15) (11) (14) (15) (4) 0 (1) (2) (7.4%)
Capex 0 0 0 (1) (1) 0 (1) 0 0 0 0 +4.2%
Free cash flow (3) (2) (6) (17) (12) (14) (16) (5) (1) (2) (2) (6.6%)
Balance, $m
Balance, $m Working capital (1) 2 11 12 16 30 11 3 (2) 3 5 n/m
Net debt 1 (1) (6) (5) (13) (27) (8) (2) (2) (2) (2) n/m
Shareholders’ equity 0 5 14 38 79 103 31 9 2 7 8 n/m
Returns, %
Returns, % ROA (77.22) (40.00) (3.73) (92.08) 11.92 (22.02) (89.43) (94.55) (57.54) (41.67) (26.73) +35.6 pt
ROIC (495.92) (3.43) (14.91) (28.48) (16.70) (16.17) (205.28) (194.30) 0.00 (27.22) (29.78) +468.7 pt
ROE (171.28) (71.61) (4.30) (195.37) 20.95 (28.47) (110.12) (133.22) (140.27) (95.30) (43.01) +76.0 pt
People
People Employees 10 11 7 182 165 154 90 52 42 42 — +17.3%
Revenue/emp, $m 0.20 0.41 0.07 0.13 0.25 0.29 0.39 0.46 0.46 0.46 — +9.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

cbdMD, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
UPC Universe Pharmaceuticals INC $7.0M — (loss-making) 4.1× −23.98% (below 0%: shrinking) −110.15% (below 0%: shrinking) −84.99% (below 0%: shrinking) 32.57% 0.00% Compare
SNOA Sonoma Pharmaceuticals, Inc. $5.1M — (loss-making) — (loss-making) +59.55% (above 0%: growing) n/m +69.31% (above 0%: growing) 40.23% (0.62%) Compare
GELS Gelteq Limited $4.9M — — — — −40.15% (below 0%: shrinking) — — Compare
YCBD cbdMD, Inc. $4.4M — (loss-making) — (loss-making) +20.55% (above 0%: growing) n/m +34.80% (above 0%: growing) 54.69% (20.36%)
APUS Apimeds Pharmaceuticals US, Inc. $4.1M — (loss-making) — — n/m −67.94% (below 0%: shrinking) — 0.00% Compare
RDHL Redhill Biopharma Ltd. $3.8M — (loss-making) — (loss-making) −90.32% (below 0%: shrinking) n/m −107.31% (below 0%: shrinking) (7.52%) 0.00% Compare
PRFX PainReform Ltd. $2.3M — (loss-making) — (loss-making) — n/m +52.56% (above 0%: growing) 0.00% 0.00% Compare
BTAIQ BioXcel Therapeutics, Inc. $2.3M — (loss-making) — (loss-making) +51.67% (above 0%: growing) n/m +51.51% (above 0%: growing) 87.91% (5,600.55%) Compare
AKAN Akanda Corp. $2.2M — — — — −472.01% (below 0%: shrinking) (197.87%) 0.00% Compare
Median of peers $4.0M — — +13.85% — −54.04% 16.29% 0.00%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 12 February 2026

Ownership

Directors and executive officers, together 6.50%
Jeffrey Porter 5.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

cbdMD, Inc. (YCBD) Latest News

2 Nov

Impact 3 · · ACCESS Newswire

24 Sep

Impact 4 · · PR Newswire

2 Sep

Impact 4 ·

14 Aug

Impact 4 · transcript

13 Aug

Impact 3 ·

3 Aug

Impact 4 ·

24 Jul

Impact 3 ·

7 Jul

Impact 3 ·

25 Jun

Impact 3 · · PR Newswire

31 May

Impact 3 · · Insider Monkey

15 May

Impact 4 · · GuruFocus.com

14 May

Impact 4 · · PR Newswire
Impact 3 · · Moby transcript
Impact 3 · · Moby transcript

11 May

Impact 5 · · ACCESS Newswire

1 Apr

Impact 4 ·

18 Feb

Impact 4 · · Moby
Impact 4 · · GuruFocus.com

17 Feb

Impact 4 · · PR Newswire

2 Feb

Impact 4 ·

29 Jan

Impact 4 · · PR Newswire

14 Jan

Impact 4 · · PR Newswire

20 Dec

Impact 4 · · GuruFocus.com

19 Dec

Impact 4 · · PR Newswire
Impact 3 · · PR Newswire

8 Dec

Impact 3 ·

21 Nov

Impact 4 · · PR Newswire

22 Oct

Impact 3 · · ACCESS Newswire

9 Oct

Impact 3 · · PR Newswire

1 Oct

Impact 3 · · Newsfile
stockrow.com/YCBD · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com